Skip to main content

Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin.

Publication ,  Conference
Erba, HP; Stadtmauer, EA; Larson, RA; Sievers, EL; Estey, EH; Lowenberg, B; Leopold, LH; Berger, MS; Herbertson, R; Appelbaum, FR
Published in: BLOOD
November 16, 2002

Duke Scholars

Published In

BLOOD

ISSN

0006-4971

Publication Date

November 16, 2002

Volume

100

Issue

11

Start / End Page

339A / 339A

Location

PHILADELPHIA, PENNSYLVANIA

Publisher

AMER SOC HEMATOLOGY

Conference Name

44th Annual Meeting of the American-Society-of-Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Erba, H. P., Stadtmauer, E. A., Larson, R. A., Sievers, E. L., Estey, E. H., Lowenberg, B., … Appelbaum, F. R. (2002). Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin. In BLOOD (Vol. 100, pp. 339A-339A). PHILADELPHIA, PENNSYLVANIA: AMER SOC HEMATOLOGY.
Erba, H. P., E. A. Stadtmauer, R. A. Larson, E. L. Sievers, E. H. Estey, B. Lowenberg, L. H. Leopold, M. S. Berger, R. Herbertson, and F. R. Appelbaum. “Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin.” In BLOOD, 100:339A-339A. AMER SOC HEMATOLOGY, 2002.
Erba HP, Stadtmauer EA, Larson RA, Sievers EL, Estey EH, Lowenberg B, Leopold LH, Berger MS, Herbertson R, Appelbaum FR. Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin. BLOOD. AMER SOC HEMATOLOGY; 2002. p. 339A-339A.

Published In

BLOOD

ISSN

0006-4971

Publication Date

November 16, 2002

Volume

100

Issue

11

Start / End Page

339A / 339A

Location

PHILADELPHIA, PENNSYLVANIA

Publisher

AMER SOC HEMATOLOGY

Conference Name

44th Annual Meeting of the American-Society-of-Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology